Reduction of Blood Activation in Patients Receiving Aprotinin During Cardiopulmonary Bypass for Coronary Artery Surgery
- 1 September 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health
- Vol. 42 (5) , M417-422
- https://doi.org/10.1097/00002480-199609000-00023
Abstract
Aprotinin reduces blood loss after cardiac surgery, particularly in patients taking aspirin. This study was performed to evaluate whether the reduction of contact phase activation by aprotinin is related to decreased complement activation during blood activation. Two hundred patients were prospectively operated on for coronary artery bypass. Aprotinin was used in the cardiopulmonary bypass (CPB) prime if aspirin was not discontinued 10 days before surgery and in patients undergoing second operation (n = 102). Blood loss was significantly reduced in patients receiving aprotinin (596 ± 309 ml vs 754 ± 329 ml without aprotinin; p = 0.0001), as was the need for transfusion (13% vs 34% without aprotinin; p = 0.0001) after surgery. Blood activation has been studied in 60 patients. Multivariate analysis showed that contact phase activation, as assessed by maximum values of C1 inhibitor/kallikrein complexes, was reduced by aprotinin treatment (pKeywords
This publication has 0 references indexed in Scilit: